Skip to main content
SpringerLink
Log in

Peyronie’s Disease: Pathophysiology and Medical Therapy

  • Chapter
Atlas of Male Sexual Dysfunction

  • 115 Accesses

Abstract

Peyronie’s disease is an acquired benign condition with potential significant impact on quality of life that can include pain, penile deformity, and erectile dysfunction (ED). Modern studies have shown the disease to be prevalent. Once thought to resolve spontaneously, it is now known that the disease consists of an active phase and a mature phase, with resolution of pain and rarely resolution of penile deformity. The disease is now known to be caused by a “trapped” inflammatory response resulting from minor trauma, hematoma formation with fibrin deposition, and resultant cytokine activity. The cytokine transforming growth factor-β1 (TGF-(β1) has demonstrated particular importance and is used in creating animal models to study the disease. This abnormal immune response may have a genetic predisposition. Modern molecular techniques, genomics, and proteomics are being applied to better understand the pathways that lead to Peyronie’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lindsay MB, Schain DM, Grambsch P, et al.: The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991, 146: 1007–1009.

    CAS  PubMed  Google Scholar 

  2. Schwarzer U, Sommer F, Klotz T, et al.: The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001, 88: 727–730.

    Article  CAS  PubMed  Google Scholar 

  3. Smith BH: Subclinical Peyronie’s disease. Am J Clin Pathol 1969, 52: 385–390.

    CAS  PubMed  Google Scholar 

  4. Williams JL, Thomas GG: The natural history of Peyronie’s disease. J Urol 1970, 103: 75–76.

    CAS  PubMed  Google Scholar 

  5. Gelbard MK, Dorey F, James K: The natural history of Peyronie’s disease. J Urol 1990, 144: 1376–1379.

    CAS  PubMed  Google Scholar 

  6. Ralph DJ, Pryor J: Peyronie’s disease. In Textbook of Erectile Dysfunction. Edited by Carson C, Kirby R, Goldstein I. Oxford, UK: Isis; 1999: 515–528.

    Google Scholar 

  7. Weidner W, Schroeder-Printzen I, Weiske WH, Vosshenrich R: Sexual dysfunction in Peyronie’s disease: an analysis of 222 patients without previous local plaque therapy. J Urol 1997, 157: 325–328.

    Article  CAS  PubMed  Google Scholar 

  8. Pryor JP: Peyronie’s disease and impotence. Acta Urol Belg 1988, 56: 317–321.

    CAS  PubMed  Google Scholar 

  9. Lopez JA, Jarow JP: Penile vascular evaluation of men with Peyronie’s disease. J Urol 1993, 149: 53–55.

    CAS  PubMed  Google Scholar 

  10. Furey CA: Peyronie’s disease: a treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957, 55: 251–266.

    Google Scholar 

  11. Jarow JP, Lowe FC: Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997, 158: 1388–1390.

    Article  CAS  PubMed  Google Scholar 

  12. Devine CJ, Jr., Somers KD, Jordan SG, Schlossberg SM: Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 1997, 157: 285–290.

    Article  PubMed  Google Scholar 

  13. Brock G, Hsu GL, Nunes L, et al.: The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 1997, 157: 276–281.

    Article  CAS  PubMed  Google Scholar 

  14. Cohen IK, Diegelmann RF, Crossland MC: Wound care and wound healing. In Principles of Surgery, edn 6. Edited by Schwartz SI, et al. New York: McGraw-Hill, Inc.; 1994: 279–303.

    Google Scholar 

  15. El-Sakka AI, Selph CA, Yen TS, Dahiya R, Lue TF: The effect of surgical trauma on rat tunica albuginea. J Urol 1998, 159: 1700–1707.

    Article  CAS  PubMed  Google Scholar 

  16. Somers KD, Dawson DM: Fibrin deposition in Peyronie’s disease plaque. J Urol 1997, 157: 311–315.

    Article  CAS  PubMed  Google Scholar 

  17. El-Sakka AI, Hassoba HM, Pillarisetty RJ, et al.: Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158: 1391–134.

    Article  CAS  PubMed  Google Scholar 

  18. El-Sakka AI, Hassoba HM, Chui RM, et al.: An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158: 2284–2290.

    Article  CAS  PubMed  Google Scholar 

  19. Casini A, Ceni E, Salzano R, et al.: Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 1997, 25: 361–367.

    Article  CAS  PubMed  Google Scholar 

  20. Poli G: Oxidative damage and fibrogenesis. Free Radic Biol Med 1997, 22: 287–305.

    Article  CAS  PubMed  Google Scholar 

  21. Poli G: Pathogenesis of liver fibrosis: role of oxidative stress. Molecular Aspects of Medicine 2000, 21: 49–98.

    Article  CAS  PubMed  Google Scholar 

  22. Geller DA, Billiar TR: Molecular biology of nitric oxide synthases. Cancer Metast Rev 1998, 17: 7–23.

    Article  CAS  Google Scholar 

  23. Nathan C: Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997, 100: 2417–2423.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Gonzalez-Cadavid NF, Magee TR, Ferrini M, et al.: Gene expression in Peyronie’s disease. Int J Impot Res 2002, 14: 361–374.

    Article  CAS  PubMed  Google Scholar 

  25. Chilton CP, Castle WM, Westwood CA, Pryor JP: Factors associated in the aetiology of Peyronie’s disease. Br J Urol 1982, 54: 748–750.

    Article  CAS  PubMed  Google Scholar 

  26. Nyberg LM, Jr., Bias WB, Hochberg MC, Walsh PC: Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982, 128: 48–51.

    PubMed  Google Scholar 

  27. Ralph DJ, Schwartz G, Moore W, et al.: The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997, 157: 291–294.

    Article  CAS  PubMed  Google Scholar 

  28. Stewart S, Malto M, Sandberg L, Colburn KK: Increased serum levels of antielastin antibodies in patients with Peyronie’s disease. J Urol 1994, 152: 105–106.

    CAS  PubMed  Google Scholar 

  29. Bystrom J, Rubio C: Induratio penis plastica Peyronie’s disease: clinical features and etiology. Scand J Urol Nephrol 1976, 10: 12–20.

    Article  CAS  PubMed  Google Scholar 

  30. Ling RS: The genetic factor in Dupuytren’s disease. J Bone Joint Surg Am 1963, 45: 709–718.

    CAS  Google Scholar 

  31. Scardino P, Scott WW: The use of tocopherols in the treatment of Peyronie’s disease. Ann N Y Acad Sci 1949, 52: 390.

    Google Scholar 

  32. Devine CJ, Jr., Horton CE: Surgical treatment of Peyronie’s disease with a dermal graft. J Urol 1974, 111: 44–49.

    PubMed  Google Scholar 

  33. Mynderse LA, Monga M: Oral therapy for Peyronie’s disease. Int J Impot Res 2002, 14: 340–344.

    Article  CAS  PubMed  Google Scholar 

  34. Chesney J: Peyronie’s disease. Br J Urol 1975, 47: 209–219.

    Article  CAS  PubMed  Google Scholar 

  35. Carson CC: Potassium para-aminobenzoate for the treatment of Peyronie’s disease: is it effective? Tech Urol 1997, 3: 135–139.

    CAS  PubMed  Google Scholar 

  36. Hasche-Klunder R: Treatment of Peyronie’s disease with para-aminobenzoacidic potassium (POTOBA). Urologe A 1978, 17: 224–227.

    CAS  PubMed  Google Scholar 

  37. Zarafonetis CJ, Horrax TM: Treatment of Peyronie’s disease with potassium para-aminobenzoate (potaba). J Urol 1959, 81: 770–772.

    CAS  PubMed  Google Scholar 

  38. Akkus E, Carrier S, Rehman J, et al.: Is colchicine effective in Peyronie’s disease? A pilot study. Urology 1994, 44: 291–295.

    Article  CAS  PubMed  Google Scholar 

  39. El-Sakka AI, Bakircioglu ME, Bhatnagar RS, et al.: The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol 1999, 161: 1980–1983.

    Article  CAS  PubMed  Google Scholar 

  40. Colletta AA, Wakefield LM, Howell FV, et al.:. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990, 62: 405–409.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP: The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992, 70: 648–651.

    Article  CAS  PubMed  Google Scholar 

  42. Teloken C, Rhoden EL, Grazziotin TM, et al.: Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol 1999, 162: 2003–2005.

    Article  CAS  PubMed  Google Scholar 

  43. Gelbard MK, Walsh R, Kaufman JJ: Collagenase for Peyronie’s disease experimental studies. Urol Res 1982, 10: 135–140.

    Article  CAS  PubMed  Google Scholar 

  44. Gelbard MK, James K, Riach P, Dorey F: Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 1993, 149: 56–58.

    CAS  PubMed  Google Scholar 

  45. Levine LA, Estrada CR: Intralesional verapamil for the treatment of Peyronie’s disease: a review. Int J Impot Res 2002, 14: 324–328.

    Article  CAS  PubMed  Google Scholar 

  46. Lee RC, Ping JA: Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990, 49: 463–466.

    Article  CAS  PubMed  Google Scholar 

  47. Levine LA, Goldman KE, Greenfield JM: Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002, 168: 621–625.

    Article  CAS  PubMed  Google Scholar 

  48. Kelami A: Classification of congenital and acquired penile deviation. Urol Int 1983, 38: 229–233.

    Article  CAS  PubMed  Google Scholar 

  49. Duncan MR, Berman B, Nseyo UO: Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991, 25: 89–94.

    Article  CAS  PubMed  Google Scholar 

  50. Ahuja S, Bivalacqua TJ, Case J, et al.: A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl 1999, 20: 444–448.

    CAS  PubMed  Google Scholar 

  51. Benson RC Jr, Knoll LD, Furlow WL: Interferon alpha 2 b in the treatment of Peyronie’s disease [abstract]. J Urol 1991, 145 (suppl): 1342.

    Google Scholar 

  52. Colombo F, Baroni P, Serrago M, et al.: Shock waves in Le Peyronie’s disease: two years experience. Eur Urol 1997, 35 (suppl 2): 124.

    Google Scholar 

  53. Manikandan R, Islam W, Srinivasan V, Evans CM: Evaluation of extracorporeal shock wave therapy in Peyronie’s disease. Urology 2002, 60: 795–799.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Jacob Rajfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nestor Gonzalez-Cadavid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark Jalkut
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, University of California, San Francisco, San Francisco, California, USA

    Tom F. Lue MD (Professor and Vice Chairman) (Professor and Vice Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rajfer, J., Gonzalez-Cadavid, N., Jalkut, M. (2004). Peyronie’s Disease: Pathophysiology and Medical Therapy. In: Lue, T.F. (eds) Atlas of Male Sexual Dysfunction. Current Medicine Group, London. https://doi.org/10.1007/978-1-4613-1087-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1087-7_11

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-4757-0811-0

  • Online ISBN: 978-1-4613-1087-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation